

MEDIA STATEMENT

PHILOGEN ANNOUNCES EXPANDED RESEARCH AND DEVELOPMENT AGREEMENT WITH ABBVIE

Siena, Italy, 15th February 2016. [Philogen S.p.A.](#) (a privately owned company) today announced that they have entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.

‘We are excited to expand our collaboration with AbbVie, a leader in the field of antibody therapeutics’ commented Dr. Duccio Neri, Philogen’s CEO. ‘The first agreement between the companies focused on osteoarthritis, and we are continuing to explore the shared scientific strengths of both companies.’

No financial details of the agreement were released.

About Philogen

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com
